AbbVie: The next chapter in SpA management: JAK inhibitors


Ansell
English
Satellite Symposium
04 June 2020 17:30 - 18:15

 Symposium Objectives:

Unburdening patients from the daily impact of SpA

  • To understand the daily burden of SpA and the associated burden of musculoskeletal symptoms like pain
  • To discuss the feasibility of the ‘treat-to-target’ approach in clinical practice and review available evidence
  • To explain that many patients do not achieve treatment targets with current therapeutic options and the need for more effective disease control

Harnessing the JAK- STAT pathway in SpA

  • To review the multiple manifestations/domains of SpA (axial involvement, peripheral arthritis, enthesitis, etc)
  • To discuss cytokine-driven pathogenesis of SpA
  • To explore the importance of the JAK-STAT pathway in SpA, and its key role in regulating the production of pro-inflammatory cytokines directly and indirectly

JAK Pathways in Immune Mediated Disease Video

  • To explore through animation how JAKs are involved in inflammatory disease pathogenesis by means of direct and indirect cytokine interaction.

Evolving the treatment paradigm in SpA with JAK inhibitors

  • To review the efficacy and safety of JAK inhibitors in clinical trials of patients with AS
  • To review the efficacy and safety of JAK inhibitors in clinical trials of patients with PsA

 


Presentations

Title Time Add to calendar
Unburdening patients from the daily impact of SpA
04 June 2020 17:30 - 17:40 Add to calendar
Harnessing the JAK- STAT pathway in SpA
04 June 2020 17:40 - 17:50 Add to calendar
JAK Pathways in Immune Mediated Disease Video
04 June 2020 17:50 - 17:52 Add to calendar
Evolving the treatment paradigm in SpA with JAK inhibitors
04 June 2020 17:52 - 18:07 Add to calendar